Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDOCC-CrEATE ctDNA-guided adjuvant chemotherapy in stage II colon cancer
NL-OMON54658Recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Aug 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of capecitabine and oxaliplatin in colon cancer (2 arms), sponsored by University Medical Center Utrecht. Started Aug 2020; status: recruiting.
02
Drugs
capecitabineoxaliplatin
03
Conditions
colon cancer
Beyond the preview
Go deeper on NL-OMON54658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54658.